217 related articles for article (PubMed ID: 16678652)
1. Impact of depression on utilization patterns of oral hypoglycemic agents in patients newly diagnosed with type 2 diabetes mellitus: a retrospective cohort analysis.
Kalsekar ID; Madhavan SS; Amonkar MM; Douglas SM; Makela E; Elswick BL; Scott V
Clin Ther; 2006 Feb; 28(2):306-18. PubMed ID: 16678652
[TBL] [Abstract][Full Text] [Related]
2. Depression in patients with type 2 diabetes: impact on adherence to oral hypoglycemic agents.
Kalsekar ID; Madhavan SS; Amonkar MM; Makela EH; Scott VG; Douglas SM; Elswick BL
Ann Pharmacother; 2006 Apr; 40(4):605-11. PubMed ID: 16551768
[TBL] [Abstract][Full Text] [Related]
3. Utilization patterns and medication adherence in patients with type 2 diabetes: variations based on type of pharmacy (chain vs independent).
Kalsekar I; Sheehan C; Peak A
Res Social Adm Pharm; 2007 Dec; 3(4):378-91. PubMed ID: 18082874
[TBL] [Abstract][Full Text] [Related]
4. Adherence with pharmacotherapy for type 2 diabetes: a retrospective cohort study of adults with employer-sponsored health insurance.
Hertz RP; Unger AN; Lustik MB
Clin Ther; 2005 Jul; 27(7):1064-73. PubMed ID: 16154485
[TBL] [Abstract][Full Text] [Related]
5. Comparisons of rosiglitazone versus pioglitazone monotherapy introduction and associated health care utilization in Medicaid-enrolled patients with type 2 diabetes mellitus.
Balkrishnan R; Arondekar BV; Camacho FT; Shenolikar RA; Horblyuk R; Anderson RT
Clin Ther; 2007 Jun; 29(6 Pt 1):1306-15. PubMed ID: 18036392
[TBL] [Abstract][Full Text] [Related]
6. Refill compliance in type 2 diabetes mellitus: a predictor of switching to insulin therapy?
Spoelstra JA; Stolk RP; Heerdink ER; Klungel OH; Erkens JA; Leufkens HG; Grobbee DE
Pharmacoepidemiol Drug Saf; 2003 Mar; 12(2):121-7. PubMed ID: 12642975
[TBL] [Abstract][Full Text] [Related]
7. Antidiabetic therapy before and 1 year after discharge for patients manifesting in-hospital hyperglycemia.
Waddell M; Flanders SJ; Golas A; Zhang Q; Juneja R
Postgrad Med; 2009 May; 121(3):61-6. PubMed ID: 19491541
[TBL] [Abstract][Full Text] [Related]
8. Health care costs and medication adherence associated with initiation of insulin pen therapy in Medicaid-enrolled patients with type 2 diabetes: a retrospective database analysis.
Pawaskar MD; Camacho FT; Anderson RT; Cobden D; Joshi AV; Balkrishnan R
Clin Ther; 2007 Jun; 29(6 Pt 1):1294-305. PubMed ID: 18036391
[TBL] [Abstract][Full Text] [Related]
9. Patient adherence and reimbursement amount for antidiabetic fixed-dose combination products compared with dual therapy among Texas Medicaid recipients.
Cheong C; Barner JC; Lawson KA; Johnsrud MT
Clin Ther; 2008 Oct; 30(10):1893-907. PubMed ID: 19014846
[TBL] [Abstract][Full Text] [Related]
10. Diffusion into use of exenatide for glucose control in diabetes mellitus: a retrospective cohort study of a new therapy.
Segal JB; Dy SM; Millman EA; Herbert R; Bass EB; Wu A
Clin Ther; 2007 Aug; 29(8):1784-94. PubMed ID: 17919559
[TBL] [Abstract][Full Text] [Related]
11. Economic impact of cardiovascular co-morbidity in patients with type 2 diabetes.
Mody R; Kalsekar I; Kavookjian J; Iyer S; Rajagopalan R; Pawar V
J Diabetes Complications; 2007; 21(2):75-83. PubMed ID: 17331855
[TBL] [Abstract][Full Text] [Related]
12. Association between extended-release niacin treatment and glycemic control in patients with type 2 diabetes mellitus: analysis of an administrative-claims database.
Ambegaonkar BM; Wentworth C; Allen C; Sazonov V
Metabolism; 2011 Jul; 60(7):1038-44. PubMed ID: 21185576
[TBL] [Abstract][Full Text] [Related]
13. The effect of depression on health care utilization and costs in patients with type 2 diabetes.
Kalsekar ID; Madhavan SM; Amonkar MM; Scott V; Douglas SM; Makela E
Manag Care Interface; 2006 Mar; 19(3):39-46. PubMed ID: 16583789
[TBL] [Abstract][Full Text] [Related]
14. Cost of diabetes: comparison of disease-attributable and matched cohort cost estimation methods.
Tunceli O; Wade R; Gu T; Bouchard JR; Aagren M; Luo W
Curr Med Res Opin; 2010 Aug; 26(8):1827-34. PubMed ID: 20491613
[TBL] [Abstract][Full Text] [Related]
15. Polypharmacy with oral antidiabetic agents: an indicator of poor glycemic control.
Willey CJ; Andrade SE; Cohen J; Fuller JC; Gurwitz JH
Am J Manag Care; 2006 Aug; 12(8):435-40. PubMed ID: 16886886
[TBL] [Abstract][Full Text] [Related]
16. Initial and subsequent therapy for newly diagnosed type 2 diabetes patients treated in primary care using data from a vendor-based electronic health record.
Brouwer ES; West SL; Kluckman M; Wallace D; Masica AL; Ewen E; Kudyakov R; Cheng D; Bowen J; Fleming NS
Pharmacoepidemiol Drug Saf; 2012 Sep; 21(9):920-8. PubMed ID: 22250059
[TBL] [Abstract][Full Text] [Related]
17. Using a pharmaco-epidemiological approach to estimate diabetes type 2 prevalence in Portugal.
Duarte-Ramos F; Cabrita J
Pharmacoepidemiol Drug Saf; 2006 Apr; 15(4):269-74. PubMed ID: 16294365
[TBL] [Abstract][Full Text] [Related]
18. Type 2 diabetes does not increase risk of depression.
Brown LC; Majumdar SR; Newman SC; Johnson JA
CMAJ; 2006 Jul; 175(1):42-6. PubMed ID: 16818907
[TBL] [Abstract][Full Text] [Related]
19. Impact of comorbid depression or anxiety on patterns of treatment and economic outcomes among patients with diabetic peripheral neuropathic pain.
Boulanger L; Zhao Y; Foster TS; Fraser K; Bledsoe SL; Russell MW
Curr Med Res Opin; 2009 Jul; 25(7):1763-73. PubMed ID: 19505204
[TBL] [Abstract][Full Text] [Related]
20. Oral hypoglycemics: increased postoperative mortality in coronary risk patients.
Jeger RV; Seeberger MD; Keller U; Pfisterer ME; Filipovic M
Cardiology; 2007; 107(4):296-301. PubMed ID: 17264509
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
